AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
Hosted on MSN20h
AstraZeneca Expands U.S. Investment PlanAstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...
Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
(Reuters) - Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback